Literature DB >> 2421425

Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach.

F O Stephens, B G Adams, P Crea.   

Abstract

Intra-arterial chemotherapy has been used preoperatively in treating patients with carcinoma of the stomach. The chemotherapy was given continuously for about one month with gastrectomy planned for three to four weeks after completion of chemotherapy. The agents used were 5-fluorouracil, Adriamycin (doxorubicin hydrochloride) and mitomycin C. The objective was to reduce the size and extent of the disease prior to subsequent surgical resection. Most of the patients had a partial response to the chemotherapy infusion. Two patients had an apparent complete response. For 16 patients who presented with the most advanced lesions, initially considered to be incurable, some palliation was achieved but long term results were not significantly changed. For 17 patients with locally invasive disease which would normally have been treated by gastrectomy alone, with an expectation of about 10 per cent five year survival time, long term results appear to have been significantly improved.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421425

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  7 in total

1.  A comparison of regional versus systemic drug injection. Adriamycin concentration in peripheral blood and gastric stump (post-Billroth II gastrectomy) in the dog.

Authors:  F K P'eng; C W Wu; T J Chang; W Y Lui
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  R0 resection in the treatment of gastric cancer: room for improvement.

Authors:  Alberto Biondi; Roberto Persiani; Ferdinando Cananzi; Marco Zoccali; Vincenzo Vigorita; Andrea Tufo; Domenico D'Ugo
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

3.  Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer.

Authors:  Antonios-Apostolos K Tentes; Sotirios K Markakidis; Charisios Karanikiotis; Aliki Fiska; Ioannis K Tentes; Vangelis G Manolopoulos; Thespis Dimitriou
Journal:  Langenbecks Arch Surg       Date:  2006-03-14       Impact factor: 3.445

Review 4.  What make differences in the outcome of adjuvant treatments for resected gastric cancer?

Authors:  Toshifusa Nakajima; Masashi Fujii
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 5.  Neoadjuvant chemotherapy for gastric cancer: update.

Authors:  U Fink; H J Stein; C Schuhmacher; H J Wilke
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

6.  Neoadjuvant chemotherapy for high-grade advanced gastric cancer.

Authors:  Y Yonemura; T Sawa; K Kinoshita; N Matsuki; S Fushida; S Tanaka; S Ohoyama; T Takashima; H Kimura; T Kamata
Journal:  World J Surg       Date:  1993 Mar-Apr       Impact factor: 3.352

7.  Treatment of multiple liver metastasis from gastric carcinoma.

Authors:  Hitoshi Ojima; Sayaka Ootake; Takehiko Yokobori; Yasushi Mochida; Yasuo Hosouchi; Yasuji Nishida; Hiroyuki Kuwano
Journal:  World J Surg Oncol       Date:  2007-06-21       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.